Risk-based decision-making in the treatment of HER2-positive early breast cancer: Recommendations based on the current state of knowledge

The HER2-positive early breast cancer (EBC) treatment landscape evolved steadily over two decades [1]. Pivotal adjuvant trials [2-6] transformed standards-of-care, catalysing transition from chemotherapy to chemotherapy-plus-trastuzumab (significantly improving disease-free/overall survival [DFS/OS]). Neoadjuvant treatment opened two major avenues: increased pathological complete response

Source: Cancer Treatment Reviews - May 19, 2021 Category: Cancer & Oncology Authors: Christian Jackisch, Patricia Cortazar, Charles E. Geyer Jr, Luca Gianni, Joseph Gligorov, Zuzana Machackova, Edith A. Perez, Andreas Schneeweiss, Sara M. Tolaney, Michael Untch, Andrew Wardley, Martine Piccart Tags: Anti-tumour Treatment Source Type: research